Daniel C. Montano
Amministratore Delegato presso Phage Biotechnology Corp.
Profilo
Daniel C.
Montano is the founder of Venturis Therapeutics, Inc. (founded in 1998) where he held the titles of Chairman, President & Chief Executive Officer from 2011 to 2014, and Phage Biotechnology Corp.
(founded in 1998) where he held the titles of Chairman, President & CEO.
Mr. Montano is also the founder of Zhittya Genesis Medicine, Inc. Currently, Mr. Montano is a Director at Cardio Phage International, Inc. (since 1998).
Previously, he was a Director at Helen of Troy Ltd.
(from 1981 to 2004).
Mr. Montano holds an MBA from the University of Southern California and an undergraduate degree from California State University-Los Angeles.
Posizioni attive di Daniel C. Montano
| Società | Posizione | Inizio |
|---|---|---|
Phage Biotechnology Corp.
 Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | Amministratore Delegato | - |
| Cardio Phage International, Inc. | Direttore/Membro del Consiglio | 01/01/1998 |
Zhittya Genesis Medicine, Inc.
 Zhittya Genesis Medicine, Inc. BiotechnologyHealth Technology Zhittya Genesis Medicine, Inc. operates as a biopharmaceutical company. It develops a biological drug which triggers angiogenesis and neurogenesis. The company was founded by Daniel Montano in 2014 and is headquartered in Las Vegas, NV. | Amministratore Delegato | - |
Precedenti posizioni note di Daniel C. Montano
| Società | Posizione | Fine |
|---|---|---|
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Amministratore Delegato | 16/09/2014 |
| HELEN OF TROY LIMITED | Direttore/Membro del Consiglio | 01/01/2004 |
Formazione di Daniel C. Montano
| University of Southern California | Masters Business Admin |
| California State University-Los Angeles | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| HELEN OF TROY LIMITED | Consumer Durables |
| Aziende private | 4 |
|---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
Phage Biotechnology Corp.
Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | Health Technology |
| Cardio Phage International, Inc. | |
Zhittya Genesis Medicine, Inc.
Zhittya Genesis Medicine, Inc. BiotechnologyHealth Technology Zhittya Genesis Medicine, Inc. operates as a biopharmaceutical company. It develops a biological drug which triggers angiogenesis and neurogenesis. The company was founded by Daniel Montano in 2014 and is headquartered in Las Vegas, NV. | Health Technology |
- Borsa valori
- Insiders
- Daniel C. Montano
